Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.08.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Yan Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Macrophages, Nanoparticles, Monocytes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Delivering therapeutic agents efficiently to inflamed regions remains an intractable challenge following myocardial ischemia-reperfusion injury (MI/RI) due to the transient nature of the enhanced permeability and retention effect, which disappears after 24 h. Leveraging the inflammation-homing and plasticity properties of circulating monocytes (MN) as hitchhiking carriers and further inducing their polarization into anti-inflammatory phenotype macrophages upon reaching the inflamed sites is beneficial for MI/RI therapy. Herein, DSS/PB@BSP nanoparticles capable of clearing reactive oxygen species and inhibiting inflammation were developed by employing hollow Prussian blue nanoparticles (PB) as carriers to encapsulate betamethasone sodium phosphate (BSP) and further modified with dextran sulfate sodium (DSS), a targeting ligand for the scavenger receptor on MN. This formulation was internalized into MN as living cell drug depots, reprogramming them into anti-inflammation type macrophages to inhibit inflammation. In vitro assessments revealed the successful construction of the nanoparticle. In a murine MI/RI model, circulating MN laden with these nanoparticles significantly enhanced drug delivery and accumulation at the cardiac injury site, exhibiting favorable therapeutic ability and promoting M2-biased differentiation. Our study provides an effective approach with minimally invasion and biosecurity that makes this nanoplatform as a promising candidate for immunotherapy and clinical translation in the treatment of MI/RI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Anesthesiology, The affiliated hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
- Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China.
- Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China; Basic Medicine Research Innovation Center for Cardiometabolic Disease, Ministry of Education, Southw…
Zitieren
APA
Liu, Y., Zhou, M., Xu, M., Wang, X., Zhang, Y., Deng, Y., Zhang, Z., Jiang, J., Zhou, X., & Li, C. (2024). Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.045
Vancouver
Liu Y, Zhou M, Xu M, Wang X, Zhang Y, Deng Y, et al. Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.045
BibTeX
@article{Liu2024,
author = {Liu, Yan and Zhou, Meiling and Xu, Maochang and Wang, Xueqin and Zhang, Yingying and Deng, Yiping and Zhang, Zongquan and Jiang, Jun and Zhou, Xiangyu and Li, Chunhong},
title = {Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.08.045}
}
EUVIMED